Literature DB >> 24384909

Giving oncolytic vaccinia virus more BiTE.

Steven M Albelda1, Steve H Thorne2.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 24384909      PMCID: PMC3978795          DOI: 10.1038/mt.2013.271

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  17 in total

1.  Landmark approval for Dendreon's cancer vaccine.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2010-06       Impact factor: 54.908

2.  Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.

Authors:  Liang-Chuan S Wang; Rachel C Lynn; Guanjun Cheng; Edward Alexander; Veena Kapoor; Edmund K Moon; Jing Sun; Zvi G Fridlender; Stuart N Isaacs; Stephen H Thorne; Steven M Albelda
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

3.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

Authors:  J A McCart; J M Ward; J Lee; Y Hu; H R Alexander; S K Libutti; B Moss; D L Bartlett
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 4.  Bispecific antibodies engage T cells for antitumor immunotherapy.

Authors:  Bryan D Choi; Mingqing Cai; Darell D Bigner; Ankit I Mehta; Chien-Tsun Kuan; John H Sampson
Journal:  Expert Opin Biol Ther       Date:  2011-03-30       Impact factor: 4.388

Review 5.  Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Authors:  Edwin J Vazquez-Cintron; Ngozi R Monu; Alan B Frey
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

6.  Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Authors:  Jun Li; Mark O'Malley; Julie Urban; Padma Sampath; Z Sheng Guo; Pawel Kalinski; Steve H Thorne; David L Bartlett
Journal:  Mol Ther       Date:  2011-01-25       Impact factor: 11.454

Review 7.  Clinical development directions in oncolytic viral therapy.

Authors:  R M Eager; J Nemunaitis
Journal:  Cancer Gene Ther       Date:  2011-03-25       Impact factor: 5.987

8.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors:  Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

9.  Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Authors:  Robin J Prestwich; Elizabeth J Ilett; Fiona Errington; Rosa M Diaz; Lynette P Steele; Tim Kottke; Jill Thompson; Feorillo Galivo; Kevin J Harrington; Hardev S Pandha; Peter J Selby; Richard G Vile; Alan A Melcher
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

10.  T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Authors:  Feng Yu; Xingbing Wang; Z Sheng Guo; David L Bartlett; Stephen M Gottschalk; Xiao-Tong Song
Journal:  Mol Ther       Date:  2013-10-17       Impact factor: 11.454

View more
  4 in total

1.  Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.

Authors:  Elena P Goncharova; Julia S Ruzhenkova; Ivan S Petrov; Sergey N Shchelkunov; Marina A Zenkova
Journal:  J Transl Med       Date:  2016-08-18       Impact factor: 5.531

Review 2.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

3.  CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma.

Authors:  Wen Lei; Qian Ye; Yuanyuan Hao; Jie Chen; Yu Huang; Liu Yang; Shibing Wang; Wenbin Qian
Journal:  Blood Cancer J       Date:  2022-02-28       Impact factor: 11.037

Review 4.  Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.

Authors:  Padma Sampath; Steve H Thorne
Journal:  Oncolytic Virother       Date:  2015-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.